Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)

Sponsor
Hoffmann-La Roche
Study ID
NCT02612077
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Observational Chemotherapy — OTHER
    No intervention - Observational standard practice chemotherapy
  • Concomitant Bevacizumab — DRUG
    No intervention - Observational concomitant bevacizumab

Study Details

This is a longitudinal, multicenter, prospective, pharmacoepidemiological study to evaluate progression free survival (PFS) in a real-life setting in participants with metastatic colorectal cancer (mCRC) starting chemotherapy combined with bevacizumab.

Key Dates

First listed
Nov 23, 2015
Start date
May 31, 2008
Status verified
Feb 2016
Primary completion
Oct 31, 2012
Completion
Oct 31, 2012

Study Design

Enrollment
765 participants (actual)

Arms

  • Arm: Observational Chemotherapy/Bevacizumab
    Observed patients receiving chemotherapy with concomitant bevacizumab

Primary Outcome Measure

Progression-free Survival [ Time Frame: within 36 months ]

Related Studies